Financial News

Markets:

Overview

News

Currencies

International

Treasuries

Abbott Laboratories (NY:ABT)

107.81 -0.15 (-0.14%)

Official Closing Price Updated: 7:00 PM EDT, Aug 7, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Abbott Laboratories

< Previous 1 2 3 4 5 6 7 8 9

...

57 58 Next >

AbbVie vs. Abbott Laboratories: Which Healthcare Stock Is a Better Buy in 2026? ↗

Today 16:44 EDT

AbbVie generates stronger free cash flow and trades at a lower forward multiple, while Abbott offers diversification and a healthier balance sheet.

Via The Motley Fool

Solventum Nears Inflection Point As It Begins to Unlock Value ↗

Today 11:35 EDT

Solventum shares gain on strong Q2 revenue, earnings, and cash flow, buybacks, and improved guidance, with analysts raising price targets amid a discounted valuation versus med/tech peers.

Via MarketBeat

Topics Initial Public Offering

This Stock Keeps Raising Its Dividend No Matter What the Market Does -- and Wall Street Thinks It's a Buy Right Now ↗

August 05, 2026

There is no end in sight for the drugmaker's dividend growth streak.

Via The Motley Fool

Topics Intellectual Property

Abbott Laboratories (NYSE:ABT): A Strong Candidate for Quality Investors ↗

July 30, 2026

Via Chartmill

Unusual volume S&P500 stocks in Thursday's session ↗

July 16, 2026

Via Chartmill

Abbott Laboratories NYSE:ABT Rises on In-Line Q2 and Raised Guidance ↗

July 16, 2026

Via Chartmill

Dividend Powerhouse: Abbott Laboratories (NYSE:ABT) Passes the Test for Sustainable Income ↗

July 10, 2026

Via Chartmill

Abbott Laboratories vs. Eli Lilly: Which Healthcare Stock Is a Better Buy in 2026? ↗

August 02, 2026

Abbott trades at half Lilly's valuation multiple, but Lilly's 45% revenue surge and 32% net margin raise the stakes for growth-focused investors.

Via The Motley Fool

Abbott Laboratories vs. Johnson & Johnson: Which Healthcare Stock Is a Better Buy in 2026? ↗

July 31, 2026

Abbott trades at a cheaper valuation but carries higher litigation risk, while J&J boasts superior profitability despite a pending talc settlement.

Via The Motley Fool

3 Dividend Stocks to Buy for a Lifetime of Passive Income ↗

July 29, 2026

These companies' recent headwinds shouldn't lead to decreased payouts.

Via The Motley Fool

Topics Intellectual Property

AbbVie Has Raised Its Dividend for 53 Straight Years and Still Looks Attractively Valued. Is This Dividend King the Smartest Buy in Healthcare Right Now? ↗

July 29, 2026

AbbVie still looks like a compelling buy at its all-time high.

Via The Motley Fool

Topics Intellectual Property

Why Wall Street Can't Get Enough of This Dividend King ↗

July 25, 2026

AbbVie has an attractive 2.7% yield, a solid pharmaceutical business, and is clearly focused on its dividend.

Via The Motley Fool

Topics Intellectual Property

3 Reasons to Buy AbbVie Stock Like There's No Tomorrow ↗

July 21, 2026

It looks like a great buy-and-hold option.

Via The Motley Fool

Topics Intellectual Property

How Will AbbVie's $10.9 Billion Acquisition of Apogee Impact Its Dividend? ↗

July 19, 2026

There's no need to panic.

Via The Motley Fool

My 2 Favorite Dividend Kings to Buy Right Now ↗

July 19, 2026

They can help stabilize your portfolio in these otherwise volatile times.

Via The Motley Fool

Topics Intellectual Property

This Dividend ETF Yields 3.2% and Is Beating the Nasdaq-100 This Year ↗

July 18, 2026

A portfolio of dividend payers with decade-long track records is outrunning the AI-heavy growth indexes.

Via The Motley Fool

Topics Artificial Intelligence ETFs Stocks

These Analysts Increase Their Forecasts On Abbott Following Better-Than-Expected Q2 Results ↗

July 17, 2026

Abbott Laboratories (NYSE:ABT) reported strong Q2 results, raising its full-year earnings outlook. Analysts have a positive outlook on ABT stock.

Via Benzinga

Why Abbott Stock Jumped Today ↗

July 16, 2026

A recent acquisition is already bearing fruit.

Via The Motley Fool

Explore the top gainers and losers within the S&P500 index in today's session. ↗

July 16, 2026

Via Chartmill

Why Abbott Laboratories Stock Is Suddenly Winning Back Wall Street ↗

July 16, 2026

Abbott's Q2 results show solid organic growth, better-than-expected margins, and improved earnings guidance, easing concerns over the Exact Sciences acquisition and boosting ABT shares.

Via MarketBeat

Dow Jones Hangs On While Memory Chips Take Another Beating ↗

July 16, 2026

Why is the Dow holding up while the Nasdaq sinks? Healthcare gains are offsetting the semiconductor carnage.

Via The Motley Fool

Topics Stocks

Exploring the top movers within the S&P500 index during today's session. ↗

July 16, 2026

Via Chartmill

Abbott Laboratories Q2 Earnings Call Highlights ↗

July 16, 2026

Abbott Laboratories (NYSE:ABT) reported second-quarter 2026 comparable sales growth of 4.8% and adjusted earnings per share of $1.31, with Chairman and Chief Executive Officer Robert Ford saying...

Via MarketBeat

Topics Earnings

Abbott Laboratories Reports Q2 2026 Results: Full Earnings Call Transcript ↗

July 16, 2026

Abbott Laboratories (NYSE:ABT) released second-quarter financial results and hosted an earnings call on Thursday. Read the complete transcript below. Benzinga APIs provide real-time access to earnings...

Via Benzinga

Topics Earnings

Abbott Laboratories (NYSE:ABT) Surprises With Q2 CY2026 Sales

July 16, 2026

Healthcare product and device company Abbott Laboratories (NYSE:ABT) beat Wall Street’s revenue expectations in Q2 CY2026, with sales up 13% year on year to ...

Via StockStory

Topics Artificial Intelligence

What's going on in today's pre-market session: S&P500 movers ↗

July 16, 2026

Via Chartmill

Abbott Labs vs. Glaukos: Which Healthcare Stock Is a Better Buy in 2026? ↗

July 08, 2026

Abbott trades at a fraction of Glaukos' valuation, but one company burns cash while the other generates billions.

Via The Motley Fool

5 Dividend Kings to Buy in July with Irristable Value and Yield ↗

July 08, 2026

Five Dividend Kings—Procter & Gamble, Hormel, Stanley Black & Decker, Genuine Parts and Lowe's—trade at discounted valuations, offering attractive yields despite near-term business headwinds.

Via MarketBeat

Eli Lilly and Novo Nordisk Are Fine -- but These 2 Stocks Could Be an Even Better Way to Invest in the GLP-1 Boom ↗

July 07, 2026

Don't sleep on these medical device leaders.

Via The Motley Fool

Topics Supply Chain

5 Dividend Kings Long-Term Investors Should Own for the Next 20 Years ↗

July 07, 2026

Investors can count on these stocks about as much as any to continue their decades-long runs of excellence.

Via The Motley Fool

< Previous 1 2 3 4 5 6 7 8 9

...

57 58 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Financial News

Abbott Laboratories (NY:ABT)

All News about Abbott Laboratories

Popular Pages